CATALOGO DEI PRODOTTI DELLA RICERCA

CINGARLINI, Sara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.654
NA - Nord America 2.502
AS - Asia 1.187
SA - Sud America 25
AF - Africa 10
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 2
Totale 6.385
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.486
GB - Regno Unito 918
CN - Cina 878
IT - Italia 365
SE - Svezia 311
IE - Irlanda 263
FR - Francia 190
DE - Germania 187
RU - Federazione Russa 183
SG - Singapore 143
FI - Finlandia 122
UA - Ucraina 34
TR - Turchia 33
BE - Belgio 27
VN - Vietnam 24
KR - Corea 23
JP - Giappone 20
HK - Hong Kong 16
BR - Brasile 12
IN - India 11
NL - Olanda 11
CA - Canada 9
ID - Indonesia 8
IR - Iran 8
LV - Lettonia 7
AT - Austria 6
ES - Italia 6
MX - Messico 6
CH - Svizzera 5
PH - Filippine 5
AU - Australia 4
AZ - Azerbaigian 4
CL - Cile 4
TG - Togo 4
AR - Argentina 3
MA - Marocco 3
UZ - Uzbekistan 3
AE - Emirati Arabi Uniti 2
BD - Bangladesh 2
CM - Camerun 2
CZ - Repubblica Ceca 2
DK - Danimarca 2
MK - Macedonia 2
NO - Norvegia 2
PE - Perù 2
PL - Polonia 2
SA - Arabia Saudita 2
TH - Thailandia 2
VE - Venezuela 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
BO - Bolivia 1
BY - Bielorussia 1
EC - Ecuador 1
EG - Egitto 1
EU - Europa 1
GR - Grecia 1
HR - Croazia 1
HU - Ungheria 1
IL - Israele 1
IM - Isola di Man 1
JO - Giordania 1
KZ - Kazakistan 1
NZ - Nuova Zelanda 1
PA - Panama 1
RO - Romania 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 6.385
Salva come PNG Salva come JPEG
Città #
Southend 866
Chandler 614
Dublin 254
Jacksonville 244
Ann Arbor 214
Woodbridge 204
Beijing 173
Ashburn 144
Verona 114
Singapore 108
Houston 86
New York 86
Lawrence 76
Princeton 76
Jinan 75
Wilmington 72
Shenyang 70
Nanjing 53
Helsinki 41
Hebei 40
Tianjin 40
Haikou 34
Redmond 32
Changsha 31
Zhengzhou 31
Brussels 27
Guangzhou 26
Milan 26
Sindelfingen 24
Nanchang 23
Seattle 23
Taiyuan 23
Bologna 22
Hangzhou 22
Ningbo 20
Lancaster 19
Redwood City 19
Seoul 18
Taizhou 18
Jiaxing 15
Hong Kong 14
Tokyo 14
Kent 13
Boardman 12
Dong Ket 12
Washington 11
Fuzhou 10
Dallas 9
Los Angeles 9
Norwalk 9
Dearborn 8
Santa Clara 8
Genova 6
Jakarta 6
Leawood 6
Rome 6
San Francisco 6
Chicago 5
Dongguan 5
Düsseldorf 5
Foresto 5
Hamburg 5
Kyoto 5
São Paulo 5
Baku 4
Cagliari 4
Fairfield 4
Grezzana 4
Lanzhou 4
Lappeenranta 4
Lomé 4
Toronto 4
Trento 4
Boydton 3
Bronx 3
Clearwater 3
Detroit 3
Falkenstein 3
Genazzano 3
Legnaro 3
Pisa 3
Riga 3
San Diego 3
San Mateo 3
Santa Marinella 3
Sejong 3
Tappahannock 3
Tashkent 3
Telgate 3
Windsor 3
Zanjan 3
Amsterdam 2
Brno 2
Buenos Aires 2
Chions 2
Cutrofiano 2
Dhaka 2
Hanoi 2
Hyderabad 2
Istanbul 2
Totale 4.405
Salva come PNG Salva come JPEG
Nome #
Whole-genome landscape of pancreatic neuroendocrine tumours 164
Anti PSMA immunotoxins activity against prostate cancer cell lines. 126
Comparison of imaging-based and pathological dimensions in pancreatic neuroendocrine tumors 118
Acquired hemophagocytic syndrome in a patient with synovial sarcoma: a case report 117
The Evolution of Surgical Strategies for Pancreatic Neuroendocrine Tumors (Pan-NENs): Time-trend and Outcome Analysis From 587 Consecutive Resections at a High-volume Institution. 117
Anti-tumor effects of toxins targeted to the prostate specific membrane antigen. 111
Perfusion Changes in Liver Metastases (LM) from Pancreatic Neuroendocrine Tumors (PanNETs) during Everolimus (E) Treatment: Update of Perfusion CT (P-CT) Study 109
Tumor Perfusion Changes During Everolimus (E) Treatment: Preliminary Results from Perfusion-CT (P-CT) Study 108
Produzione e validazione preclinica di un anticorpo anti-PSMA per diagnostica ed immunotargeting 107
Mixed adenoneuroendocrine carcinomas of the gastrointestinal tract: targeted next-generation sequencing suggests a monoclonal origin of the two components 106
Role of Combined Ga-68-DOTATOC and F-18-FDG Positron Emission Tomography/Computed Tomography in the Diagnostic Workup of Pancreas Neuroendocrine Tumors Implications for Managing Surgical Decisions 105
Can histogram analysis of MR images predict aggressiveness in pancreatic neuroendocrine tumors? 105
The prostate specific membrane antigen regulates the expression of IL-6 and CCL5 in prostate tumor cells by activating the MAPK pathways. 105
IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer 104
Apical transport and folding of prostate-specific membrane antigen occurs independent of glycan processing. 103
Are Cystic Pancreatic Neuroendocrine Tumors an Indolent Entity? Results from a Single-Center Surgical Series 102
EpCAM a possible target for immunotoxin treatments of PSMA positive and negative prostate cancer cells 101
Anticorpo monoclonale isolato o suo frammento legante l'antigene specifico di membrana della prostata, suoi coniugati e suoi usi 101
Characterization of a new anti PSCA monoclonal antibody and scFv fragment for diagnosis and immunotherapy of prostate, pancreatic and bladder carcinoma. 100
Ingegnerizzazione di un vettore per espressione di frammenti anticorpali (scFv) biotinilati in procarioti, purificazione ed analisi funzionale 100
The prostate specific membrane antigen regulates the expression of IL-6 and CCL-5 in prostate tumour cells by activating the MAPK pathways 100
A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer 100
Corrigendum: Whole-genome landscape of pancreatic neuroendocrine tumours 100
CT Enhancement and 3D Texture Analysis of Pancreatic Neuroendocrine Neoplasms 100
Pancreatic neuroendocrine neoplasms: Magnetic resonance imaging features according to grade and stage 100
Tumor Perfusion Changes During Everolimus (E) Treatment: Preliminary Results from Perfusion-CT (P-CT) Study 99
Production of a biotinylated anti-PSMA single-chain antibody fragment (scFv) for imaging and radioimmunotherapy 98
Anti PSCA Monoclonal Antibody and scFv-Fragment for Immunotherapy of Prostate, Pancreatic and Bladder Carcinoma 98
A prospective non-randomised single-center study comparing laparoscopic and robotic distal pancreatectomy 96
Investigation of Properties of Anti-Prostate Specific Membrane Antigen-targeted Gold Nanoparticles as Drug Carriers in Tumor Therapy 95
ESGAR 2016 Book of Abstracts 93
Perfusion CT Changes in Liver Metastases from Pancreatic Neuroendocrine Tumors During Everolimus Treatment 89
Adjuvant Chemotherapy For Resected Non-Small-Cell Lung Cancer: Future Perspectives For Clinical Research 89
Isolated monoclonal antibody or fragment thereof binding prostate specific membrane antigen, conjugates and uses thereof 88
Preclinical studies of a new anti-psma (prostate specific membrane antigen) antibody for diagnosis and immunotargeting 87
Anti-prostate specific membrane antigen targeted gold nanoparticles in tumor therapy and diagnosis 87
Tumor Targeting with Guided Silica Nanopartilces for Prostate Cancer Therapy 87
Prognostication and response assessment in liver and pancreatic tumors: The new imaging 87
Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic 87
Liver Tumor Burden in Pancreatic Neuroendocrine Tumors: CT Features and Texture Analysis in the Prediction of Tumor Grade and 18F-FDG Uptake 86
Generazione di nuovi anticorpi anti prostate stem cell antigen (PSCA) e loro caratterizzazione al fine di un futuro utilizzo nella terapia e nella diagnosi dei carcinomi prostatico, pancreatico e della vescica 85
Digital Subtraction of Magnetic Resonance Images Improves Detection and Characterization of Pancreatic Neuroendocrine Neoplasms 84
Pancreatic neuroendocrine neoplasms: MRI features and correlation with their histological grade 80
Pathological complete response in a patient affected by multiple synchronous, breast and lung primary malignancies: a case report and review of the literature 79
Solid non-functioning endocrine tumors of the pancreas: correlating computed tomography and pathology 79
The development of PARP as a successful target for cancer therapy 79
Ultra-Mutation in IDH Wild-Type Glioblastomas of Patients Younger than 55 Years is Associated with Defective Mismatch Repair, Microsatellite Instability, and Giant Cell Enrichment 78
Dual-tracer (68Ga-DOTATOC and 18F-FDG-)-PET/CT scan and G1-G2 non-functioning pancreatic neuroendocrine tumors: A single-center retrospective evaluation of 124 non-metastatic resected cases 76
PSMA-Specific CAR-Engineered T Cells Eradicate Disseminated Prostate Cancer in Preclinical Models 75
Streptozotocin/5-Fluorouracil (STZ/5FU) Chemotherapy in G1-G2 Pancreatic Neuroendocrine Tumors (pNETs): Single Institution Experience 74
Pulmonary Adenocarcinoma With Enteric Differentiation: Immunohistochemistry and Molecular Morphology 74
Profiling mTOR pathway in neuroendocrine tumors 72
Histogram analysis of ADC maps: assessment of intra-tumoral heterogeneity and correlation with the biological behavior of pancreatic neuroendocrine neoplasms 72
Patterns of recurrence after resection for pancreatic neuroendocrine tumors: who, when, and where? 71
Endoscopic ultrasound-guided fine-needle aspiration for the diagnosis and grading of pancreatic neuroendocrine tumors: a retrospective analysis of 110 cases 71
Imaging presentation of pancreatic neuroendocrine neoplasms 70
Prognostic Stratification and Therapeutic Response Assessment in Liver and Pancreatic Tumors: the New Imaging 69
3D-CT texture analysis of neuroendocrine pancreatic neoplasms 68
Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours 68
Minimally Invasive Surgery for Pancreatic Neuroendocrine Tumors: Why Not? 67
Pancreatic Neuroendocrine Neoplasms: Clinical Value of Diffusion-Weighted Imaging 66
Multi-institutional Development and External Validation of a Nomogram to Predict Recurrence After Curative Resection of Pancreatic Neuroendocrine Tumors 64
Alternative Lengthening of Telomeres (ALT) in Pancreatic Neuroendocrine Tumors: Ready for Prime-Time in Clinical Practice? 62
Clinical presentation, genotype-phenotype correlations, and outcome of pancreatic neuroendocrine tumors in Von Hippel-Lindau syndrome 60
Normal Tissue Perfusion Changes During Everolimus Treatment: Preliminary Results from a Functional Vascular Study 59
Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives 58
Differentiation of pancreatic neuroendocrine tumor grade comparing 3D CT texture analysis and relative CT enhancement ratios 53
Efficacy and Toxicity Analysis of mFOLFIRINOX in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms 52
Mutational and copy number asset of primary sporadic neuroendocrine tumors of the small intestine 52
Is Laparoscopic CME Right Hemicolectomy an Optimal Indication for NET of the Right Colon and Terminal Ileum? 51
DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association 50
Juvenile polyposis diagnosed with an integrated histological, immunohistochemical and molecular approach identifying new SMAD4 pathogenic variants 50
Platinum-Based Treatment for Well- and Poorly Differentiated Pancreatic Neuroendocrine Neoplasms 47
Ki-67 assessment of pancreatic neuroendocrine neoplasms: Systematic review and meta-analysis of manual vs. digital pathology scoring 41
Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size 38
Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells 33
Pattern of disease recurrence and treatment after surgery for nonfunctioning well-differentiated pancreatic neuroendocrine tumors 30
Is the Morphological Subtype of Extra-Pulmonary Neuroendocrine Carcinoma Clinically Relevant? 30
Transcriptome analysis of primary sporadic neuroendocrine tumours of the intestine identified three different molecular subgroups 28
Surgery for pancreatic neuroendocrine tumors during the COVID-19 pandemic: a retrospective cohort from a high-volume center 22
Glucagon-Producing Pancreatic Neuroendocrine Tumors (Glucagonomas) are Enriched in Aggressive Neoplasms with ARX and PDX1 Co-expression, DAXX/ATRX Mutations, and ALT (Alternative Lengthening of Telomeres) 7
Totale 6.519
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.579
article - articoli 14.981
book - libri 0
conference - conferenze 6.578
curatela - curatele 0
other - altro 270
patent - brevetti 520
selected - selezionate 0
volume - volumi 230
Totale 45.158
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020521 0 0 0 39 68 60 79 32 49 59 52 83
2020/2021644 79 101 44 89 82 50 14 37 41 17 62 28
2021/2022786 65 256 18 70 37 17 14 44 23 18 53 171
2022/20231.625 96 211 148 287 108 429 38 88 173 9 25 13
2023/2024835 29 66 75 82 90 166 25 50 9 65 144 34
2024/2025436 104 112 108 112 0 0 0 0 0 0 0 0
Totale 6.519